{"id":4781,"date":"2023-11-23T14:04:22","date_gmt":"2023-11-23T14:04:22","guid":{"rendered":"https:\/\/www.value-dx.eu\/?p=4781"},"modified":"2023-11-23T14:05:15","modified_gmt":"2023-11-23T14:05:15","slug":"progress-and-insights-from-the-prudence-and-adequate-trials","status":"publish","type":"post","link":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/","title":{"rendered":"Progress and insights from the PRUDENCE and ADEQUATE trials"},"content":{"rendered":"\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-jzkylawd-ba86e75d702405f62001a756eb35483d\">\n.avia-section.av-jzkylawd-ba86e75d702405f62001a756eb35483d{\nbackground-color:#08b4a0;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_1'  class='avia-section av-jzkylawd-ba86e75d702405f62001a756eb35483d main_color avia-section-default avia-no-border-styling  avia-builder-el-0  el_before_av_section  avia-builder-el-first  avia-bg-style-parallax container_wrap fullsize'  ><div class='container av-section-cont-open' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-4781'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-kx4q0z2f-de2740dd28bc4a5ec2df2c706116f82a\">\n#top .av-special-heading.av-kx4q0z2f-de2740dd28bc4a5ec2df2c706116f82a{\npadding-bottom:10px;\n}\nbody .av-special-heading.av-kx4q0z2f-de2740dd28bc4a5ec2df2c706116f82a .av-special-heading-tag .heading-char{\nfont-size:25px;\n}\n.av-special-heading.av-kx4q0z2f-de2740dd28bc4a5ec2df2c706116f82a .av-subheading{\nfont-size:15px;\n}\n<\/style>\n<div  class='av-special-heading av-kx4q0z2f-de2740dd28bc4a5ec2df2c706116f82a av-special-heading-h3 blockquote modern-quote modern-centered  avia-builder-el-1  el_before_av_codeblock  avia-builder-el-first  av-linked-heading'><h3 class='av-special-heading-tag '  itemprop=\"headline\"  >Progress and insights from the PRUDENCE and ADEQUATE trials<\/h3><div class=\"special-heading-border\"><div class=\"special-heading-inner-border\"><\/div><\/div><\/div>\n\n<\/div><\/div><\/main><!-- close content main element --><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-1cjng-9db903d36b325f87b66fb9ba7e96614e\">\n.avia-section.av-1cjng-9db903d36b325f87b66fb9ba7e96614e{\nbackground-color:#1b7ca4;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_2'  class='avia-section av-1cjng-9db903d36b325f87b66fb9ba7e96614e main_color avia-section-default avia-no-border-styling  avia-builder-el-3  el_after_av_section  el_before_av_section  avia-bg-style-scroll container_wrap fullsize'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-4781'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-k0i4yzrj-318dd765ad6f41d2fe86b741f8548ed0\">\n.flex_column.av-k0i4yzrj-318dd765ad6f41d2fe86b741f8548ed0{\nborder-radius:0px 0px 0px 0px;\npadding:50px 5% 50px 5%;\n}\n<\/style>\n<div  class='flex_column av-k0i4yzrj-318dd765ad6f41d2fe86b741f8548ed0 av_one_full  avia-builder-el-4  el_before_av_one_fifth  avia-builder-el-first  first flex_column_div  '     ><section  class='av_textblock_section av-yfjs-bdca154287e84706a717077d4cd17983 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock'  itemprop=\"text\" ><p><em>Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.<\/em><\/p>\n<p>The <strong>PRUDENCE<\/strong> trial focuses on a comprehensive point-of-care testing strategy for CRP, strep A, influenza A+B, and SARS-CoV-2, targeting patients with lower or upper respiratory symptoms. The trial spans primary and long-term care across multiple countries with varying diagnostic practices. Unlike past studies, PRUDENCE considers patient recovery alongside antibiotic prescribing. Through this, we aim to provide valuable insights into the effectiveness and cost-effectiveness of a broader point-of-care testing strategy in the context of respiratory infections, addressing the shortcomings of previous studies.<\/p>\n<p><em>Patient Recruitment and Progress Update<\/em><\/p>\n<p>Launched in December 2021 with a goal of enlisting 2500 participants, the trial has successfully recruited 2159 patients, achieving over 86% of its target, with primary care currently at 2006 patients and long-term care at 153 patients. The teams in Georgia, Greece, Ireland and the UK have reached their network recruitment target already. Recruitment progress typically exhibits a seasonal trend, with a drop-off during Summer months. The trial includes a sampling sub-study, currently underway in long-term care and soon to be rolled out in Primary Care in the UK and Georgia. Despite challenges, including the impact of COVID-19 regulations and varying symptom presentations, the long-term care facility network is evolving positively. Trial recruitment will end in January.<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-4778 size-full\" src=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/PRUDENCE-graph.png\" alt=\"\" width=\"584\" height=\"319\" srcset=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/PRUDENCE-graph.png 584w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/PRUDENCE-graph-300x164.png 300w\" sizes=\"(max-width: 584px) 100vw, 584px\" \/><\/p>\n<p>The <strong>ADEQUATE<\/strong> trial aims to assess antibiotic prescription practices and hospitalization outcomes in pediatric emergency departments across Europe. The trial employs randomization to standard care and intervention arms, with patients presenting with lower respiratory tract infections. In the intervention arm, the Biofire respiratory panel assay is utilized, offering rapid testing for 24 pathogens, aiding clinical decisions without prescribing specific guidelines. The primary endpoints include antibiotic prescription rates and hospitalization duration, with a focus on generating immediately applicable evidence for routine settings.<\/p>\n<p><em>Patient Recruitment and Progress Update<\/em><\/p>\n<p>Six out of seven sites have been activated and have recruited patients, with the site in Thessaloniki, Greece being the top recruiter and have already reached its recruitment target. Currently at 85% recruitment, the trial plans to reach its goal of 520 participants. Recruitment fluctuations, influenced by seasonal patterns and the impact of the COVID-19 pandemic, are taken into account. The trial anticipates a surge in enrollment during the upcoming winter season, with a projected closure of all sites by February to March 2024.<\/p>\n<p><img decoding=\"async\" class=\"aligncenter wp-image-4780\" src=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48.png\" alt=\"\" width=\"550\" height=\"487\" srcset=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48.png 741w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48-300x266.png 300w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48-705x624.png 705w\" sizes=\"(max-width: 550px) 100vw, 550px\" \/><img decoding=\"async\" class=\"aligncenter wp-image-4779\" src=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.36.png\" alt=\"\" width=\"550\" height=\"476\" srcset=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.36.png 746w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.36-300x260.png 300w, https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.36-705x610.png 705w\" sizes=\"(max-width: 550px) 100vw, 550px\" \/><\/p>\n<\/div><\/section><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-3b8mw-b506a38e8d00a7f4906eea669cebc6be\">\n.flex_column.av-3b8mw-b506a38e8d00a7f4906eea669cebc6be{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-3b8mw-b506a38e8d00a7f4906eea669cebc6be av_one_fifth  avia-builder-el-6  el_after_av_one_full  el_before_av_one_fifth  first flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-2lzlw-3d25ff9ce16d4f57844d3b5b4e0627c5\">\n.flex_column.av-2lzlw-3d25ff9ce16d4f57844d3b5b4e0627c5{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-2lzlw-3d25ff9ce16d4f57844d3b5b4e0627c5 av_one_fifth  avia-builder-el-7  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-7tlo-f8416bb2afc61a4a130355b19410e269\">\n.flex_column.av-7tlo-f8416bb2afc61a4a130355b19410e269{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-7tlo-f8416bb2afc61a4a130355b19410e269 av_one_fifth  avia-builder-el-8  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  column-top-margin'     ><div  class='av-social-sharing-box av-k0i4kjks-6d3450111d8e25130dca06d4190760bd av-social-sharing-box-minimal  avia-builder-el-9  avia-builder-el-no-sibling  av-social-sharing-box-fullwidth'><div class=\"av-share-box\"><ul class=\"av-share-box-list noLightbox\"><li class='av-share-link av-social-link-twitter avia_social_iconfont' ><a target=\"_blank\" aria-label=\"Share on X\" href='https:\/\/twitter.com\/share?text=Progress%20and%20insights%20from%20the%20PRUDENCE%20and%20ADEQUATE%20trials&#038;url=https:\/\/www.value-dx.eu\/?p=4781' data-av_icon='\ue932' data-av_iconfont='entypo-fontello'  title='' data-avia-related-tooltip='Share on X'><span class='avia_hidden_link_text'>Share on X<\/span><\/a><\/li><li class='av-share-link av-social-link-linkedin avia_social_iconfont' ><a target=\"_blank\" aria-label=\"Share on LinkedIn\" href='https:\/\/linkedin.com\/shareArticle?mini=true&#038;title=Progress%20and%20insights%20from%20the%20PRUDENCE%20and%20ADEQUATE%20trials&#038;url=https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/' data-av_icon='\ue8fc' data-av_iconfont='entypo-fontello'  title='' data-avia-related-tooltip='Share on LinkedIn'><span class='avia_hidden_link_text'>Share on LinkedIn<\/span><\/a><\/li><li class='av-share-link av-social-link-mail avia_social_iconfont' ><a  aria-label=\"Share by Mail\" href='mailto:?subject=Progress%20and%20insights%20from%20the%20PRUDENCE%20and%20ADEQUATE%20trials&#038;body=https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/' data-av_icon='\ue805' data-av_iconfont='entypo-fontello'  title='' data-avia-related-tooltip='Share by Mail'><span class='avia_hidden_link_text'>Share by Mail<\/span><\/a><\/li><\/ul><\/div><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-1gk3g-e035d72a73a93486e640208771f4a074\">\n.flex_column.av-1gk3g-e035d72a73a93486e640208771f4a074{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-1gk3g-e035d72a73a93486e640208771f4a074 av_one_fifth  avia-builder-el-10  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-yzdo-63e3a9df4e270ed0fd52b6929706fb26\">\n.flex_column.av-yzdo-63e3a9df4e270ed0fd52b6929706fb26{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-yzdo-63e3a9df4e270ed0fd52b6929706fb26 av_one_fifth  avia-builder-el-11  el_after_av_one_fifth  avia-builder-el-last  flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<\/p>\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-k0i590fy-427634ed8909a6d2106239c938ad0962\">\n.avia-section.av-k0i590fy-427634ed8909a6d2106239c938ad0962{\nbackground-color:#1b7ca4;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_3'  class='avia-section av-k0i590fy-427634ed8909a6d2106239c938ad0962 main_color avia-section-default avia-no-border-styling  avia-builder-el-12  el_after_av_section  avia-builder-el-last  avia-bg-style-scroll container_wrap fullsize'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-4781'><div class='entry-content-wrapper clearfix'>\n\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":152,"featured_media":4780,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-4781","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Progress and insights from the PRUDENCE and ADEQUATE trials - value-dx<\/title>\n<meta name=\"description\" content=\"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Progress and insights from the PRUDENCE and ADEQUATE trials - value-dx\" \/>\n<meta property=\"og:description\" content=\"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"value-dx\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-23T14:04:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-23T14:05:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48.png\" \/>\n\t<meta property=\"og:image:width\" content=\"741\" \/>\n\t<meta property=\"og:image:height\" content=\"656\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Leandra\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ValueDx\" \/>\n<meta name=\"twitter:site\" content=\"@ValueDx\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leandra\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/\"},\"author\":{\"name\":\"Leandra\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\"},\"headline\":\"Progress and insights from the PRUDENCE and ADEQUATE trials\",\"datePublished\":\"2023-11-23T14:04:22+00:00\",\"dateModified\":\"2023-11-23T14:05:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/\"},\"wordCount\":1482,\"image\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Screenshot-2023-11-22-at-13.37.48.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/\",\"name\":\"Progress and insights from the PRUDENCE and ADEQUATE trials - value-dx\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Screenshot-2023-11-22-at-13.37.48.png\",\"datePublished\":\"2023-11-23T14:04:22+00:00\",\"dateModified\":\"2023-11-23T14:05:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\"},\"description\":\"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Screenshot-2023-11-22-at-13.37.48.png\",\"contentUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Screenshot-2023-11-22-at-13.37.48.png\",\"width\":741,\"height\":656},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2023\\\/11\\\/23\\\/progress-and-insights-from-the-prudence-and-adequate-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/homepage\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Progress and insights from the PRUDENCE and ADEQUATE trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/\",\"name\":\"value-dx\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.value-dx.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\",\"name\":\"Leandra\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/author\\\/leandra\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Progress and insights from the PRUDENCE and ADEQUATE trials - value-dx","description":"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/","og_locale":"en_US","og_type":"article","og_title":"Progress and insights from the PRUDENCE and ADEQUATE trials - value-dx","og_description":"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.","og_url":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/","og_site_name":"value-dx","article_published_time":"2023-11-23T14:04:22+00:00","article_modified_time":"2023-11-23T14:05:15+00:00","og_image":[{"width":741,"height":656,"url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48.png","type":"image\/png"}],"author":"Leandra","twitter_card":"summary_large_image","twitter_creator":"@ValueDx","twitter_site":"@ValueDx","twitter_misc":{"Written by":"Leandra","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/#article","isPartOf":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/"},"author":{"name":"Leandra","@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d"},"headline":"Progress and insights from the PRUDENCE and ADEQUATE trials","datePublished":"2023-11-23T14:04:22+00:00","dateModified":"2023-11-23T14:05:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/"},"wordCount":1482,"image":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/","url":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/","name":"Progress and insights from the PRUDENCE and ADEQUATE trials - value-dx","isPartOf":{"@id":"https:\/\/www.value-dx.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48.png","datePublished":"2023-11-23T14:04:22+00:00","dateModified":"2023-11-23T14:05:15+00:00","author":{"@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d"},"description":"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.","breadcrumb":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/#primaryimage","url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48.png","contentUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48.png","width":741,"height":656},{"@type":"BreadcrumbList","@id":"https:\/\/www.value-dx.eu\/index.php\/2023\/11\/23\/progress-and-insights-from-the-prudence-and-adequate-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.value-dx.eu\/index.php\/homepage\/"},{"@type":"ListItem","position":2,"name":"Progress and insights from the PRUDENCE and ADEQUATE trials"}]},{"@type":"WebSite","@id":"https:\/\/www.value-dx.eu\/#website","url":"https:\/\/www.value-dx.eu\/","name":"value-dx","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.value-dx.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d","name":"Leandra","url":"https:\/\/www.value-dx.eu\/index.php\/author\/leandra\/"}]}},"jetpack_featured_media_url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/11\/Screenshot-2023-11-22-at-13.37.48.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts\/4781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/users\/152"}],"replies":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/comments?post=4781"}],"version-history":[{"count":0,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts\/4781\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/media\/4780"}],"wp:attachment":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/media?parent=4781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/categories?post=4781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/tags?post=4781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}